Ownership and insider activity for Natera, Inc. (NTRA): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations.
Price
| Price | $403.95 (closing price, October 29, 2026) |
| Market Cap | $58.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-21 | Sheena Jonathan | S-Sale | 200 | $81K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 962 | $393K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 627 | $257K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 605 | $249K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 211 | $87K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 125 | $52K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 255 | $106K |
| 2026-10-21 | Sheena Jonathan | S-Sale | 165 | $69K |
| 2026-10-16 | Sheena Jonathan | S-Sale | 142 | $57K |
| 2026-10-16 | Sheena Jonathan | S-Sale | 215 | $86K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $15.3M | $12.6M | $46.4M | $61.9M | $48.7M | $84.4M | $466.1M | $642.1M | $945.6M | $1.08B |
| Short-term Investments | $130.9M | $106.2M | $107.5M | $379.1M | $688.6M | $829.9M | $432.3M | $236.9M | $22.7M | 0 |
| Receivables | $13.4M | $44.1M | $62.2M | $53.4M | $78.6M | $122.1M | $244.4M | $278.3M | $314.2M | $296.5M |
| Inventory | $6.4M | $9.0M | $13.6M | $12.4M | $20.0M | $26.9M | $35.4M | $40.8M | $44.7M | $68.4M |
| Total Current Assets | $174.1M | $180.6M | $240.5M | $523.2M | $862.7M | $1.09B | $1.21B | $1.26B | $1.38B | $1.50B |
| Property, Plant & Equipment | $32.3M | $29.7M | $24.3M | $47.0M | $54.7M | $124.5M | $164.3M | $167.7M | $248.2M | $349.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $141.1M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $373.7M |
| Total Assets | $210.7M | $214.6M | $268.2M | $582.7M | $932.2M | $1.24B | $1.39B | $1.44B | $1.66B | $2.51B |
| Accounts Payable | $11.5M | $8.5M | $14.6M | $8.6M | $8.1M | $27.2M | $31.1M | $15.0M | $34.9M | $33.2M |
| Short-term Debt | $49.6M | $50.1M | $50.2M | $50.1M | $50.1M | $50.1M | $80.3M | $80.4M | $80.4M | $80.3M |
| Total Current Liabilities | $96.4M | $105.6M | $114.0M | $179.9M | $199.1M | $219.0M | $310.5M | $307.3M | $344.0M | $441.2M |
| Long-term Debt | 0 | $73.1M | $73.4M | $73.7M | $202.5M | $280.4M | $281.7M | $282.9M | 0 | 0 |
| Total Liabilities | $104.2M | $189.2M | $236.0M | $303.9M | $445.9M | $583.2M | $688.7M | $676.4M | $465.3M | $795.6M |
| Retained Earnings | -$345.8M | -$446.4M | -$574.5M | -$699.2M | -$929.3M | -$1.39B | -$1.94B | -$2.38B | -$2.57B | -$2.78B |
| Total Equity | $106.5M | $25.4M | $32.2M | $278.7M | $486.2M | $653.3M | $705.7M | $765.3M | $1.20B | $1.71B |
| Total Debt | $49.6M | $123.2M | $123.5M | $155.8M | $281.1M | $397.2M | $446.2M | $442.0M | $187.1M | $214.4M |
| Net Debt | -$96.5M | $4.3M | -$30.4M | -$285.2M | -$456.2M | -$517.0M | -$452.2M | -$437.0M | -$781.2M | -$861.8M |
| Working Capital | $77.7M | $75.1M | $126.5M | $343.3M | $663.6M | $874.2M | $901.3M | $951.3M | $1.03B | $1.06B |
Financial Health
| Debt / Equity | 0.13 |
| Current Ratio | 3.00 |
| Piotroski F-Score | 5 |
| Altman Z-Score | 23.09 |
Profitability
| Return on Equity | -11.73% |
| Return on Invested Capital | -10.02% |
| Return on Assets | -7.24% |
| Gross Margin | 65.30% |
| Operating Margin | -10.70% |
| Net Margin | -7.11% |
Related companies: BLLN · VCYT · TMO · 0R0H.L · DHR · 0R2B.L · A · 0HAV.L
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of NTRA: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks